EligibleTrials

Clinical trials recruiting for Metastatic or Unresectable Melanoma

Fewer than 3 recruiting trials found.

1
Recruiting trials
8
US states with sites
2
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 1

Drugs and treatments being studied

InterventionTrials
NX-16071
Paclitaxel1

Where trials are recruiting (top US states)

StateRecruiting trials
California1
Colorado1
Illinois1
North Carolina1
Oklahoma1
Texas1
Virginia1
Washington1

Top cities

Aurora, Colorado 1Chapel Hill, North Carolina 1Charlottesville, Virginia 1Chicago, Illinois 1Duarte, California 1Houston, Texas 1Los Angeles, California 1Oklahoma City, Oklahoma 1San Francisco, California 1Seattle, Washington 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Metastatic or Unresectable Melanoma often also study these conditions. Each links to its own recruiting-trial list.

Triple Negative Breast Cancer (TNBC) 35Prostate cancer 1234Non-small cell lung cancer 507Microsatellite Stable Colorectal Carcinoma 3Metastatic Urothelial Carcinoma 5Metastatic Castration-resistant Prostate Cancer (mCRPC) 18Melanoma 487Lung cancer 2180Head and Neck Squamous Cell Carcinoma 42GastroEsophageal Junction (GEJ) Cancer 3

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Metastatic or Unresectable Melanoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.